Publications
Bashir J, Nalla P, Peter R, Bain SC, Chudleigh R. A case series of DKA occurring in patients receiving treatment with SGLT-2 inhibitors. Diabetes Obes Metab. 2018 Mar 1. doi: 10.1111/dom.13271. [Epub ahead of print] No abstract available. PMID: 29493069
Moser O, Eckstein ML, McCarthy O, Deere R, Bain SC, Haahr HL, Zijlstra E, Heise T, Bracken RM. Heart rate dynamics during cardio-pulmonary exercise testing are associated with glycemic control in individuals with type 1 diabetes. PLoS One. 2018 Apr 2;13(4):e0194750. doi: 10.1371/journal.pone.0194750. eCollection 2018. PMID: 29608593
Gray BJ, Stephens JW, Thomas M, Williams SP, Davies CA, Bracken RM. Role of cardiorespiratory fitness in lifetime cardiovascular risk prediction models: a cross-sectional analysis. The Lancet. 2017 Nov 23. Volume 390, Supplement 3, November 2017, Page S40. doi:10.1016/S0140-6736(17)32975-6
Di Battista E, Bracken RM, Stephens JW, Rice S, Thomas M, Williams S, Mellalieu S. Workplace delivery of a dietitian‐led cardiovascular disease and type 2 diabetes prevention programme: A qualitative study of participants’ experiences in the context of Basic Needs Theory. Nutrition Bulletin. 10 November 2017. 42(4), 309-320. doi:10.1111/nbu.12292
Chudleigh, R., Bain, S.C. Semaglutide. GLP-1 receptor agonist, Treatment of type 2 diabetes. Drugs Fut 2017, 42(8): 479. DOI: 10.1358/dof.2017.042.08.2653526
Bain SC. The Cellnovo Insulin Delivery System. Eur Endocrinol. 2017 Apr;13(1):13-16. doi: 10.17925/EE.2017.13.01.13. Epub 2017 Apr 3. No abstract available. PMID: 29632599
Reed J; Kanamarlapudi V; Bain S. Mechanism of cardiovascular disease benefit of glucagon-like peptide 1 agonists. Cardiovascular Endocrinology. Publish Ahead of Print():, DEC 2017. DOI: 10.1097/XCE.0000000000000147. Issn Print: 2162-688X
Reed J; Kanamarlapudi V; Bain S. Mechanism of cardiovascular disease benefit of glucagon-like peptide 1 agonists. Cardiovascular Endocrinology. Publish Ahead of Print():, DEC 2017. DOI: 10.1097/XCE.0000000000000147. Issn Print: 2162-688X
Dasgupta I, Banerjee D, Chowdhury TA, De P, Wahba M, Bain S, Frankel A, Fogarty D, Pokrajac A, Winocour PH. Association of British Clinical Diabetologists (ABCD) and Renal Association clinical guidelines: Hypertension management and renin-angiotensin-aldosterone system blockade in patients with diabetes, nephropathy and/or chronic kidney disease. British Journal of Diabetes. 17(4), 160-164. DOI: https://doi.org/10.15277/bjd.2017.152
Jardine MJ, Mahaffey KW, Neal B, Agarwal R, Bakris GL, Brenner BM, Bull S, Cannon CP, Charytan DM, de Zeeuw D, Edwards R, Greene T, Heerspink HJL, Levin A, Pollock C, Wheeler DC, Xie J, Zhang H, Zinman B, Desai M, Perkovic V; CREDENCE study investigators. The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics. Am J Nephrol. 2017 Dec 13;46(6):462-472. doi: 10.1159/000484633. [Epub ahead of print] PMID: 29253846